← Back to Screener
Integra LifeSciences Holdings (IART)
Price$10.84
Favorite Metrics
Price vs S&P 500 (26W)-29.51%
Price vs S&P 500 (4W)18.11%
Market Capitalization$874.85M
All Metrics
P/CF (Annual)17.36x
Book Value / Share (Quarterly)$13.40
P/TBV (Annual)5.18x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.63%
Cash Flow / Share (Quarterly)$-0.58
Price vs S&P 500 (YTD)-13.83%
Gross Margin (TTM)56.62%
Net Profit Margin (TTM)-31.58%
EPS (TTM)$-6.74
10-Day Avg Trading Volume0.77M
EPS Excl Extra (TTM)$-6.74
Revenue Growth (5Y)3.57%
EPS (Annual)$-6.74
ROI (Annual)-17.81%
Gross Margin (Annual)56.62%
Net Profit Margin (5Y Avg)-1.01%
Cash / Share (Quarterly)$3.39
Revenue Growth QoQ (YoY)-1.74%
ROA (Last FY)-14.34%
Revenue Growth TTM (YoY)1.53%
EBITD / Share (TTM)$-6.27
ROE (5Y Avg)-5.13%
Operating Margin (TTM)-30.20%
Cash Flow / Share (Annual)$-0.58
P/B Ratio0.84x
P/B Ratio (Quarterly)0.93x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.53x
Net Interest Coverage (TTM)-7.31x
ROA (TTM)-13.80%
EV / EBITDA (TTM)88.36x
EPS Incl Extra (Annual)$-6.74
Current Ratio (Annual)2.54x
Quick Ratio (Quarterly)1.25x
3-Month Avg Trading Volume0.78M
52-Week Price Return-34.07%
EV / Free Cash Flow (Annual)16.19x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.33
P/S Ratio (Annual)0.54x
Asset Turnover (Annual)0.45x
52-Week High$17.54
Operating Margin (5Y Avg)1.78%
EPS Excl Extra (Annual)$-6.74
CapEx CAGR (5Y)8.40%
Tangible BV CAGR (5Y)-2.59%
26-Week Price Return-25.52%
Quick Ratio (Annual)1.25x
13-Week Price Return-16.12%
Total Debt / Equity (Annual)1.78x
Current Ratio (Quarterly)2.54x
Enterprise Value$2,495.903
Revenue / Share Growth (5Y)5.78%
Asset Turnover (TTM)0.44x
Book Value / Share Growth (5Y)-5.70%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.54x
Pretax Margin (Annual)-34.46%
Cash / Share (Annual)$3.39
3-Month Return Std Dev44.97%
Gross Margin (5Y Avg)61.07%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-17.88%
EBITDA Interim CAGR (5Y)-12.73%
ROE (Last FY)-49.50%
Net Interest Coverage (Annual)-7.31x
EPS Basic Excl Extra (Annual)$-6.74
P/FCF (TTM)23.68x
Receivables Turnover (TTM)5.93x
EV / Free Cash Flow (TTM)26.03x
Total Debt / Equity (Quarterly)1.78x
EPS Incl Extra (TTM)$-6.74
Receivables Turnover (Annual)5.93x
ROI (TTM)-17.19%
P/S Ratio (TTM)0.54x
Pretax Margin (5Y Avg)-0.54%
Revenue / Share (Annual)$21.33
Tangible BV / Share (Annual)$4.38
Forward P/E4.62x
Free OCF CAGR (5Y)-31.13%
Price vs S&P 500 (52W)-63.90%
Year-to-Date Return-11.19%
5-Day Price Return12.21%
EPS Normalized (Annual)$-6.74
ROA (5Y Avg)-0.72%
Net Profit Margin (Annual)-31.58%
Month-to-Date Return17.09%
Cash Flow / Share (TTM)$2.73
EBITD / Share (Annual)$-6.27
Operating Margin (Annual)-30.25%
LT Debt / Equity (Annual)1.66x
P/CF (TTM)17.36x
ROI (5Y Avg)-1.01%
LT Debt / Equity (Quarterly)1.66x
EPS Basic Excl Extra (TTM)$-6.74
P/TBV (Quarterly)5.05x
P/B Ratio (Annual)0.93x
Inventory Turnover (TTM)1.54x
Pretax Margin (TTM)-34.46%
Book Value / Share (Annual)$13.40
Price vs S&P 500 (13W)-16.81%
Beta1.13x
P/FCF (Annual)58.28x
Revenue / Share (TTM)$21.30
ROE (TTM)-44.49%
52-Week Low$8.70
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.71
2.71
2.71
2.75
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
IARTIntegra LifeSciences Holdings | 0.54x | 3.57% | 56.62% | -30.20% | $10.84 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Integra Lifesciences Holdings Corp is a New Jersey-based medical devices company specializing in regenerative therapy, extremity orthopedics, and neurosurgical solutions. The company operates through two main segments—Codman Specialty Surgical, which generates the majority of revenue, and Tissue Technologies—with a global presence spanning North America, Europe, and Asia Pacific, supported by substantial U.S. market sales.